We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark
Read MoreHide Full Article
Pacira BioSciences, Inc. (PCRX - Free Report) reported third-quarter 2021 earnings of 72 cents per share, beating the Zacks Consensus Estimate of 66 cents. The company reported earnings of 68 cents per share in the year-ago quarter.
Total revenues increased 8.7% to $127.7 million in the third quarter of 2021 from the year-earlier figure of $117.5 million owing to a continuous strong uptake of Exparel. The top line, however, missed the Zacks Consensus Estimate of $130 million.
Shares of Pacira have declined 10.3% so far this year compared with the industry’s decrease of 14.1%.
Image Source: Zacks Investment Research
Quarter in Detail
Pacira’s top line mainly comprises product revenues, other product sales and royalty revenues.
Exparel net product sales were $121.9 million, up 7.2% from $113.7 million generated in the year-ago quarter. However, sale of the drug decreased 6.3% on a sequential basis.
Exparel/bupivacaine liposome injectable suspension sales came in at $0.7 million in the reported quarter compared with $0.4 million in the year-ago quarter. Exparel is a liposome injection of bupivacaine, indicated for a single-dose administration into the surgical site to produce postsurgical analgesia.
Iovera system generated sales worth $4.2 million in the third quarter of 2021, reflecting a sequential increase of 10.5% and a year-over-year rise of 55.5%.
Royalty revenues came in at $0.9 million in the reported quarter compared with $0.6 million in the year-ago period.
Research and development (R&D) expenses (excluding stock-based compensation) declined 21.3% to $10.4 million.
Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) decreased 10.9% year over year to $39.7 million in the reported quarter.
2021 Outlook
Pacira is not providing guidance for 2021 due to the COVID-19 pandemic still negatively impacting sales. As a result, it is reporting monthly intra-quarter unaudited net product sales until the company gains enough visibility around the impacts of COVID-19.
Recent Updates
Last month, Pacira entered into a definitive agreement to acquire Flexion Therapeutics, Inc. for $8.50 per share in cash plus one non-tradeable contingent value right worth up to $8 per share in cash. With this acquisition, Pacria is looking to strengthen its position in the non-opioid pain management market. The transaction is expected to close later in the fourth quarter of 2021.
Flexion’s only marketed drug Zilretta (triamcinolone acetonide extended-release injectable suspension) was approved in 2017 as the first and the only extended-release intra-articular therapy providing relief to osteoarthritis (OA) patients with knee pain.
In October 2021, Pacira received a Paragraph IV Certification notice letter, which stated that New Jersey-based eVenus Pharmaceutical Laboratories, Inc. submitted an abbreviated new drug application (ANDA) to the FDA, seeking authorization for the manufacturing and marketing of a generic version of Pacira’s flagship product Exparel in the United States.
Pacira BioSciences, Inc. Price, Consensus and EPS Surprise
Enanta Pharmaceuticals’ loss per share estimates have narrowed 10.2% for 2021 and 16.3% for 2022 over the past 60 days. The stock has skyrocketed 104.7% year to date.
Endo International’s earnings estimates have been revised 1.3% upward for 2021 and 0.4% upward for 2022 over the past 60 days.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Shutterstock
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark
Pacira BioSciences, Inc. (PCRX - Free Report) reported third-quarter 2021 earnings of 72 cents per share, beating the Zacks Consensus Estimate of 66 cents. The company reported earnings of 68 cents per share in the year-ago quarter.
Total revenues increased 8.7% to $127.7 million in the third quarter of 2021 from the year-earlier figure of $117.5 million owing to a continuous strong uptake of Exparel. The top line, however, missed the Zacks Consensus Estimate of $130 million.
Shares of Pacira have declined 10.3% so far this year compared with the industry’s decrease of 14.1%.
Quarter in Detail
Pacira’s top line mainly comprises product revenues, other product sales and royalty revenues.
Exparel net product sales were $121.9 million, up 7.2% from $113.7 million generated in the year-ago quarter. However, sale of the drug decreased 6.3% on a sequential basis.
Exparel/bupivacaine liposome injectable suspension sales came in at $0.7 million in the reported quarter compared with $0.4 million in the year-ago quarter. Exparel is a liposome injection of bupivacaine, indicated for a single-dose administration into the surgical site to produce postsurgical analgesia.
Iovera system generated sales worth $4.2 million in the third quarter of 2021, reflecting a sequential increase of 10.5% and a year-over-year rise of 55.5%.
Royalty revenues came in at $0.9 million in the reported quarter compared with $0.6 million in the year-ago period.
Research and development (R&D) expenses (excluding stock-based compensation) declined 21.3% to $10.4 million.
Selling, general and administrative (SG&A) expenses (excluding stock-based compensation) decreased 10.9% year over year to $39.7 million in the reported quarter.
2021 Outlook
Pacira is not providing guidance for 2021 due to the COVID-19 pandemic still negatively impacting sales. As a result, it is reporting monthly intra-quarter unaudited net product sales until the company gains enough visibility around the impacts of COVID-19.
Recent Updates
Last month, Pacira entered into a definitive agreement to acquire Flexion Therapeutics, Inc. for $8.50 per share in cash plus one non-tradeable contingent value right worth up to $8 per share in cash. With this acquisition, Pacria is looking to strengthen its position in the non-opioid pain management market. The transaction is expected to close later in the fourth quarter of 2021.
Flexion’s only marketed drug Zilretta (triamcinolone acetonide extended-release injectable suspension) was approved in 2017 as the first and the only extended-release intra-articular therapy providing relief to osteoarthritis (OA) patients with knee pain.
In October 2021, Pacira received a Paragraph IV Certification notice letter, which stated that New Jersey-based eVenus Pharmaceutical Laboratories, Inc. submitted an abbreviated new drug application (ANDA) to the FDA, seeking authorization for the manufacturing and marketing of a generic version of Pacira’s flagship product Exparel in the United States.
Pacira BioSciences, Inc. Price, Consensus and EPS Surprise
Pacira BioSciences, Inc. price-consensus-eps-surprise-chart | Pacira BioSciences, Inc. Quote
Zacks Rank & Stocks to Consider
Pacira currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector include Enanta Pharmaceuticals, Inc. (ENTA - Free Report) and Endo International plc , both carrying a Zacks Rank #2 (Buy) at present.You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Enanta Pharmaceuticals’ loss per share estimates have narrowed 10.2% for 2021 and 16.3% for 2022 over the past 60 days. The stock has skyrocketed 104.7% year to date.
Endo International’s earnings estimates have been revised 1.3% upward for 2021 and 0.4% upward for 2022 over the past 60 days.